GLAXOSMITHKLINE Pricing & Demo

Are you from this Company?
GLAXOSMITHKLINE
Write a Review
Greater London, UK
2000
$10BN to $50BN
Enterprise
86 Likes
83 Buyers Negotiating
Summary
No Summary And Details

Popular Comparisons

Discussions

Strengths
  • +10
    Monovalent
  • +11
    Multivalent
  • +10
    DTP (diphtheria, pertussis, tetanus)
  • +6
    Hepatitis
  • +12
    Human Papilloma Virus
  • +11
    Influenza
  • +13
    Meningococcal disease
  • +7
    MMR (Measles-Mumps-Rubella)
  • +9
    Others
  • +9
    Pnemococcal disease
  • +14
    Polio
  • +5
    Rotavirus
  • +8
    Varicella
  • +10
    Intradermal (ID)
  • +8
    Intramuscular (IM)
  • +9
    Intranasal
  • +7
    Oral
  • +11
    Subcutaneous (SC)
  • +12
    Conjugate Vaccines
  • +13
    Inactivated and subunit vaccines
Cautions
  • -14
    Live attenuated vaccines
  • -6
    Recombinant vaccines
  • -5
    Toxoid Vaccine
  • -7
    Breadth and Depth of Product Offerings
  • -8
    Focus on Product Innovation
  • -10
    Product Pipeline
  • -9
    Route of Administration
I agree to 360Quadrants Terms of use and privacy policy
Success
info
Error
Company Size :
  Enterprise
  SME
  Startup
logo-360
  • saved

    You haven’t saved anything yet

    To save, search for Vendors by
    Name or Category, then tap the heart